Neophyr (Nitric Oxide)

Nitric Oxide, the active ingredient in Neophyr, is a nitric oxide donor presented as a medical gas for inhalation use. It is employed to manage elevated pulmonary arterial pressure in adults with pulmonary hypertension and in newborns with persistent pulmonary hypertension.

GNH USA supplies Neophyr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides regulatory‑approved product for global distribution. Neophyr is available for procurement by healthcare institutions seeking reliable pulmonary vasodilator solutions.

Neophyr, a pulmonary vasodilator, is indicated for conditions characterized by high pulmonary arterial pressure.

- Pulmonary hypertension: reduces pulmonary arterial pressure and improves exercise tolerance in adult patients. - Neonatal persistent pulmonary hypertension: provides selective pulmonary vasodilation to enhance oxygenation in affected newborns.

Adverse reactions to inhaled nitric oxide may vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often related to vasodilation. - Flushing: transient warmth and reddening of the skin. - Dizziness: sensation of light‑headedness, usually temporary.

Serious or Rare Side Effects: - Severe hypotension: marked drop in systemic blood pressure requiring medical intervention. - Methemoglobinemia: elevated methemoglobin levels that impair oxygen delivery. - Allergic reaction: rash, itching, or anaphylaxis in susceptible individuals.

When prescribing Neophyr, clinicians should consider several safety measures.

- Pregnancy: safety not established; use only if potential benefit outweighs risk. - Neonates: requires specialized delivery equipment and continuous monitoring. - Concomitant vasodilators: risk of additive hypotensive effects; monitor blood pressure. - Methemoglobinemia history: avoid use in patients with known susceptibility. - Renal impairment: monitor because altered clearance may affect response. - Store at below 25°C: keep cylinders in original packaging, protect from heat and direct sunlight.

Neophyr may interact with other agents that influence vascular tone or hemoglobin.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors: additive pulmonary vasodilation may cause severe hypotension. - Other nitric oxide donors (e.g., nitroglycerin): risk of profound systemic hypotension.

Moderate Interactions (Monitor Closely): - General anesthetics: may enhance vasodilatory response, requiring blood pressure monitoring. - Beta‑blockers: may blunt compensatory tachycardia during hypotensive episodes. - Inhaled anesthetic gases: potential for increased methemoglobin formation, necessitating periodic methemoglobin level checks.